U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07684131) titled 'EWALL-PH OBSERVARTORY 2022' on April 04.
Brief Summary: An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Study Start Date: Jan. 15, 2024
Study Type: OBSERVATIONAL
Condition:
Acute Lymphoblastic Leukemia
Recruitment Status: RECRUITING
Sponsor: Versailles Hospital
Information provided by (Responsible Party): Philippe ROUSSELOT, Versailles Hospital
Disclaimer: Curated by HT Syndication....